Supplementary Figure 5 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Barbara Herkert,Audrey Kauffmann, Sandra Mollé,Christian Schnell, Thomas Ferrat,Hans Voshol, Janina Juengert, Hélène Erasimus, Grégory Marszalek, Malika Kazic-Legueux,Eric Billy,David Ruddy,Mark Stump,Daniel Guthy, Mitko Ristov,Keith Calkins,Sauveur-Michel Maira,William R. Sellers,Francesco Hofmann,Michael N. Hall,Saskia M. Brachmann

crossref（2023）

引用 0|浏览0

暂无评分

摘要

MAPK pathway inhibition synergizes with PI3Kβ inhibition in WM-266-4, but not in A-375. A-D) Determination of PI3K/BRAF and PI3K/MEK inhibitor synergy in WM-266-4 (A+B) and A-375 (C+D) using proliferation assays. Dose matrices highlight percentages of proliferation inhibition relative to DMSO with 100 indicating complete block of proliferation and >100 indicative of cell death. SS, synergy score. PI3Kβi1/2=rac-KIN-193/GSK-2636771, panPI3Ki=GDC0941, PI3Kαi=BYL719, BRAFi=LGX818, MEKi=MEK162

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplementary Figure 5 from Maximizing the Efficacy of MAPK-Targeted Treatment in &lt;i&gt;PTEN&lt;/i&gt;&lt;sup&gt;LOF&lt;/sup&gt;&lt;i&gt;/BRAF&lt;/i&gt;&lt;sup&gt;MUT&lt;/sup&gt; Melanoma through PI3K and IGF1R Inhibition

Supplementary Figure 5 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition